Jonathan W. Day
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Neuropeptides and Animal Physiology, Receptor Mechanisms and Signaling, Pancreatic function and diabetes, Regulation of Appetite and Obesity
Most-Cited Works
- → A new glucagon and GLP-1 co-agonist eliminates obesity in rodents(2009)624 cited
- → Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents(2012)134 cited
- → Glucagon regulation of energy metabolism(2010)81 cited
- → Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein(2022)52 cited
- → An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif(2022)46 cited
- → Identification of metal ion binding peptides containing unnatural amino acids by phage display(2013)43 cited
- → Charge inversion at position 68 of the glucagon and glucagon‐like peptide‐1 receptors supports selectivity in hormone action(2010)23 cited
- → Functional association of the N‐terminal residues with the central region in glucagon‐related peptides(2011)17 cited
- → A hydrophobic site on the GLP-1 receptor extracellular domain orients the peptide ligand for signal transduction(2013)16 cited
- → Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial(2025)16 cited